drugset / Trial / NCT03502694
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to determine in hospitalized adult participants infected with human metapneumovirus (hMPV - a virus closely related to respiratory syncytial virus (RSV) and has been identified as an important cause of acute respiratory infections, affecting all age groups) the dose-response relationship of multiple regimens of lumicitabine on antiviral activity based on nasal hMPV shedding using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) assay.
Timeline
- Start
- 2018-11-05
- Primary completion
- 2019-04-30
- Completion
- 2020-10-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lumicitabine | Small molecule | 250 mg | Oral |
| Subject | Lumicitabine | Small molecule | 500 mg | Oral |